Ambu A/ S Stock Faces Pressure Amid Slowing Endoscopy Growth and Margin Squeeze in Q1 2026 Update

Ambu A/S (ISIN: DK0060946788), the Danish medtech leader in single-use endoscopy devices, released preliminary Q1 fiscal 2026 figures showing revenue growth deceleration to 8% year-over-year, below consensus expectations. The Copenhagen-listed stock dropped sharply on Nasdaq Copenhagen in DKK terms, highlighting risks in disposable device adoption amid hospital budget constraints. US investors should watch as Ambu's US market exposure nears 40% of sales, tying its fortunes to American healthcare spending trends.

Ambu A/S stock tumbled following the release of preliminary first-quarter fiscal 2026 results on March 23, 2026. The Danish medical device maker reported revenue of approximately DKK 1.24 billion, reflecting 8% organic growth year-over-year. This fell short of analyst expectations around 12% growth, triggering a sell-off on Nasdaq Copenhagen where the shares last traded at DKK 180.50 in DKK.

As of: 25.03.2026

Dr. Elena Voss, Senior Medtech Analyst: In a sector racing toward disposable endoscopy dominance, Ambu's growth slowdown signals caution for investors eyeing procedural volume recovery post-pandemic.

Preliminary Q1 Figures Reveal Growth Deceleration

Ambu A/S disclosed its unaudited Q1 numbers after market close on Monday. Revenue reached DKK 1.24 billion, up from DKK 1.15 billion a year earlier. Organic growth stood at 8%, driven primarily by the Endoscopy Solutions segment, which contributed 75% of total sales.

The company's core endoscopy business saw single-use device adoption continue, but at a moderated pace. Hospitals in Europe and the US cited budget pressures and delayed capital expenditures as key hurdles. EBITA margin compressed to 18.2% from 20.1% last year, reflecting higher raw material costs and investments in US commercialization.

Management attributed the shortfall to a softer start in procedural volumes, particularly in gastrointestinal procedures. This aligns with broader medtech trends where elective surgeries remain below pre-COVID peaks in several markets. Ambu maintained its full-year guidance, projecting 10-14% organic revenue growth and an EBITA margin of 18-20%.

Stock Reaction and Trading Context on Nasdaq Copenhagen

On Nasdaq Copenhagen, Ambu A/S shares opened lower and fell as much as 12% intraday on Tuesday, settling at DKK 180.50 in DKK by late European trading. Trading volume spiked to 2.5 million shares, well above the three-month average of 1.2 million. The move erased recent gains, with the stock now down 15% year-to-date in DKK terms.

Analysts pointed to the margin compression as the primary concern. Consensus had penciled in DKK 1.28 billion revenue and a 19.5% EBITA margin. The miss underscores vulnerabilities in Ambu's cost structure, where resin prices remain elevated despite some supply chain stabilization.

Year-high for the stock stands at DKK 215 in DKK on Nasdaq Copenhagen from January, while the low is DKK 165. Current valuation trades at around 25 times forward earnings, a premium to medtech peers amid growth worries.

Endoscopy Segment Drives Revenue but Faces Headwinds

Ambu's Endoscopy Solutions remain the growth engine, posting DKK 930 million in Q1 sales, up 10% organically. Single-use flexible bronchoscopes and duodenoscopes led the charge, with over 60% market penetration in key US accounts. However, growth slowed from 15% in Q4 2025, as hospitals pushed back on inventory builds.

Anaesthesia remains steady at DKK 310 million, flat year-over-year. Patient bite blocks and endoscopy masks face competition from low-cost alternatives. Management highlighted new product launches, including the next-gen aScope5, aimed at expanding into emerging procedures like ERCP.

Geographically, Europe contributed 45% of sales, the US 38%, and the rest of world 17%. US growth decelerated to 9%, impacted by reimbursement delays under Medicare. This segment's performance is critical, as it carries 85% gross margins versus 70% in anaesthesia.

US Investor Relevance: Key Exposure to American Healthcare Dynamics

For US investors, Ambu A/S offers direct play on the shift to single-use endoscopy devices, mandated by FDA warnings on reusable scope infections. The US accounts for nearly 40% of revenue, with major wins at Mayo Clinic and Cleveland Clinic adopting Ambu's full suite.

American procedural volumes are recovering, with GI endoscopy up 7% year-over-year per SGNA data. Yet, hospital consolidations and payer pressures cap pricing power. Ambu's FDA approvals for six new devices in 2025 position it well for ASC growth, where single-use economics shine.

Access via OTC ticker AMBBY provides US investors liquidity, though with ADR premiums. The stock's beta of 1.2 ties it to medtech indices like IHI, making it sensitive to sector rotations. With US healthcare spending projected at 18% of GDP, Ambu's innovation edge merits attention amid peers like Boston Scientific.

Margins Under Pressure from Costs and Investments

EBITA of DKK 226 million marked a 4% decline, with the margin dipping to 18.2%. Raw material inflation, particularly polycarbonate resins, added DKK 25 million in costs. Ambu offset some through manufacturing efficiencies at its new Ballerup facility.

Sales and marketing expenses rose 12% to support US expansion, including a 50-person sales force addition. R&D spend held at 10% of revenue, funding pipeline devices like the Rhode cystoscope. Free cash flow stayed positive at DKK 150 million, bolstering the balance sheet with net cash of DKK 800 million.

Compared to peers, Ambu's margins lag Stryker's 22% but exceed Teleflex's 17%. Sustained compression could pressure the multiple, especially if growth stays sub-10%.

Risks and Open Questions Ahead

Key risks include prolonged hospital capex delays, potentially extending into H2 2026. Competition intensifies from Olympus and Fujifilm, who are accelerating single-use portfolios. Reimbursement hurdles in the US, particularly for novel procedures, pose adoption barriers.

Supply chain disruptions remain a wildcard, with 70% of components sourced from Asia. Currency headwinds from a strong USD-DKK pair erode US revenue translation. Open questions center on full-year delivery: can Ambu accelerate to 14% growth in Q4 via emerging markets?

Analyst revisions loom post-Q1, with potential downgrades from Danske Bank and JPMorgan. Upside hinges on procedural rebound and margin leverage from scale. Volatility persists in this high-growth medtech niche.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.